je.st
news
Elan reorganises Tysabri revenues
2013-02-06 10:46:00| Biotech - Topix.net
Biogen Idec is to take full ownership of blockbuster multiple sclerosis drug Tysabri after agreeing to pay Irish partner Elan $3.25 billion plus future royalties on sales of the drug.
Tags: revenues
elan
tysabri
reorganises
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||